Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Breast 1

Conditions

Breast Cancer Female 1

Interventions

Magnetic Resonance Spectroscopy 5pembrolizumab 4Biopsy 4durvalumab 3atezolizumab 3Radiotherapy 3Radiosurgery 3Cyclophosphamide 3Bevacizumab 3palbociclib 2niraparib 2abemaciclib 2Trastuzumab 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Melphalan 2Letrozole 2Ketamine 2Irinotecan 2Hydrocortisone 2Gemcitabine 2Fluorodeoxyglucose F18 2Ferrosoferric Oxide 2Dexamethasone 2Curcumin 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Withdrawn × Aromatase Inhibitors × Clear all
NCT04088032 2020-07-16

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Stony Brook University

Phase EARLY_PHASE1 Withdrawn
BreastOther neoplasm

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡